2022
DOI: 10.1016/j.jid.2021.06.040
|View full text |Cite
|
Sign up to set email alerts
|

Immune Checkpoint Blockade and Skin Toxicity Pathogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
14
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(15 citation statements)
references
References 98 publications
0
14
0
1
Order By: Relevance
“…As described above, ICIs such as anti-PD1 Abs and anti-CTLA4 Abs have become anchor drugs in the treatment of advanced melanoma [ 1 , 2 , 5 ] ( Table 1 ). ICIs significantly prolong survival in patients with metastatic melanoma [ 1 , 2 , 13 ], but the associated risk of irAEs is an important consideration [ 46 , 47 , 48 ]. Among such irAEs, dermatological toxicities are among the most common, well-known and earliest onset irAEs [ 46 , 47 , 48 ]; however, especially in clinical studies, dermatological toxicities are categorized as “skin eruption”, and they were not further described.…”
Section: Adverse Events Of Icismentioning
confidence: 99%
See 1 more Smart Citation
“…As described above, ICIs such as anti-PD1 Abs and anti-CTLA4 Abs have become anchor drugs in the treatment of advanced melanoma [ 1 , 2 , 5 ] ( Table 1 ). ICIs significantly prolong survival in patients with metastatic melanoma [ 1 , 2 , 13 ], but the associated risk of irAEs is an important consideration [ 46 , 47 , 48 ]. Among such irAEs, dermatological toxicities are among the most common, well-known and earliest onset irAEs [ 46 , 47 , 48 ]; however, especially in clinical studies, dermatological toxicities are categorized as “skin eruption”, and they were not further described.…”
Section: Adverse Events Of Icismentioning
confidence: 99%
“…ICIs significantly prolong survival in patients with metastatic melanoma [ 1 , 2 , 13 ], but the associated risk of irAEs is an important consideration [ 46 , 47 , 48 ]. Among such irAEs, dermatological toxicities are among the most common, well-known and earliest onset irAEs [ 46 , 47 , 48 ]; however, especially in clinical studies, dermatological toxicities are categorized as “skin eruption”, and they were not further described. Since cutaneous irAEs could present with various manifestations, and since the treatment for these cutaneous irAEs is different for each phenotype [ 46 , 47 ], the classification of cutaneous irAEs is important for the safe use of ICIs.…”
Section: Adverse Events Of Icismentioning
confidence: 99%
“…This prevents immune cells from reaching tumour cells and attacking them. [ 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 ]. PD-L1 is present in exosomes released from melanoma cells [ 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 ]; however, exosomes derived from metastasised melanoma cells have a higher PD-L1 content than those derived from primary focal melanoma cells.…”
Section: Ev-mediated Immune Escape Of Cancer Cellsmentioning
confidence: 99%
“…Melanoma elicits a particularly strong immune response, and multiple immune checkpoint inhibitors have been approved by the US Food and Drug Administration for the treatment of melanoma [ 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 ]. Interestingly, based on PD-L1 levels in exosomes, patients who are most likely to respond to checkpoint inhibitors can be identified and the response to these drugs can be evaluated [ 162 , 194 , 196 , 197 , 198 , 199 ].…”
Section: Ev-mediated Immune Escape Of Cancer Cellsmentioning
confidence: 99%
“…For example, patients with melanoma, who developed vitiligo as irAE after administration of ICI, often enjoyed favorable antimelanoma outcomes 1 . In addition, irAE occurs most quickly and frequently in the skin, 2 often resulting in discontinuing the use of ICI. Skin toxicities as irAE have been reported to occur in more than one‐third of the treated patients, and include pruritus, eczema‐like spongiotic dermatitis, lichenoid reactions, psoriasis, vitiligo, and other autoimmune manifestations such as bullous pemphigoid, alopecia areata, and dermatomyositis 3 …”
Section: Introductionmentioning
confidence: 99%